{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:57:34Z","timestamp":1777611454822,"version":"3.51.4"},"reference-count":97,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Aspergillus spp. are spore forming molds; a subset of which are clinically relevant to humans and can cause significant morbidity and mortality. A. fumigatus causes chronic infection in patients with chronic lung disease such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). In patients with CF, A. fumigatus infection can lead to allergic disease, such as allergic bronchopulmonary aspergillosis (ABPA) which is associated with high rates of hospitalizations for acute exacerbations and lower lung function. ABPA results from TH2 immune response to Aspergillus antigens produced during hyphal growth, marked by high levels of IgE and eosinophil activation. Clinically, patients with ABPA experience difficulty breathing; exacerbations of disease and are at high risk for bronchiectasis and lung fibrosis. Oral corticosteroids are used to manage aspects of the inflammatory response and antifungal agents are used to reduce fungal burden and lower the exposure to fungal antigens. As the appreciation for the severity of fungal infections has grown, new therapies have emerged that aim to improve treatment and outcomes for patients with CF.<\/jats:p>","DOI":"10.3390\/antibiotics10040357","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T22:09:01Z","timestamp":1616969341000},"page":"357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Allergic Diseases Caused by Aspergillus Species in Patients with Cystic Fibrosis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1996-2491","authenticated-orcid":false,"given":"Aidan K.","family":"Curran","sequence":"first","affiliation":[{"name":"Pulmatrix Inc., 99 Hayden Avenue, Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Hava","sequence":"additional","affiliation":[{"name":"Synlogic Inc., 301 Binney Street, Cambridge, MA 02142, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09059180.00001011","article-title":"Pulmonary aspergillosis: A clinical review","volume":"20","author":"Kousha","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/CMR.00055-08","article-title":"Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis","volume":"22","author":"Dagenais","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/318133","article-title":"Management of Invasive Pulmonary Aspergillosis in Hematology Patients: A Review of 87 Consecutive Cases at a Single Institution","volume":"31","author":"Yeghen","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","article-title":"Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell trans-plants after nonmyeloablative conditioning","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-7022-4-14","article-title":"Fungal allergy in asthma\u2013state of the art and research needs","volume":"4","author":"Denning","year":"2014","journal-title":"Clin. Transl. Allergy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/ijmr.IJMR_1187_19","article-title":"Allergic bronchopulmonary aspergillosis","volume":"151","author":"Agarwal","year":"2020","journal-title":"Indian J. Med. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2500\/aap.2019.40.4262","article-title":"Allergic bronchopulmonary aspergillosis","volume":"40","author":"Patel","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/02770903.2019.1599387","article-title":"Serological analysis of sensitization in allergic bronchopulmonary aspergillosis: A study on allergen components and interspecies relationships","volume":"57","author":"Kuwabara","year":"2019","journal-title":"J. Asthma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cea.13557","article-title":"Clinical relevance of Aspergillus fumigatus sensitization in cystic fibrosis","volume":"50","author":"Eickmeier","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1183\/09031936.00139513","article-title":"Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis","volume":"43","author":"Moss","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1513\/pats.200908-086AL","article-title":"Allergic Bronchopulmonary Aspergillosis","volume":"7","author":"Patterson","year":"2010","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2013.04.007","article-title":"Novel immunologic classification of aspergillosis in adult cystic fibrosis","volume":"132","author":"Baxter","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/13693786.2012.738312","article-title":"Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults","volume":"51","author":"Denning","year":"2013","journal-title":"Med. Mycol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/376525","article-title":"Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis\u2014State of the Art: Cystic Fibrosis Foundation Consensus Conference","volume":"37","author":"Stevens","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.23822\/EurAnnACI.1764-1489.121","article-title":"Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis patients using two different diagnos-tic criteria","volume":"52","author":"Maleki","year":"2020","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.09-1103","article-title":"The Effect of Chronic Infection with Aspergillus fumigatus on Lung Function and Hospitalization in Patients with Cystic Fibrosis","volume":"137","author":"Amin","year":"2010","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1469-0691.2010.03429.x","article-title":"Aspergillus fumigatus colonization in cystic fibrosis: Implications for lung function?","volume":"17","author":"Stellato","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/13693780802609604","article-title":"Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis\u2014A review","volume":"47","author":"Pihet","year":"2009","journal-title":"Med Mycol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2014.10.005","article-title":"Molecular epidemiology of Aspergillus collected from cystic fibrosis patients","volume":"14","author":"Sabino","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/CMR.00068-09","article-title":"The Changing Microbial Epidemiology in Cystic Fibrosis","volume":"23","author":"Lipuma","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0954-6111(99)90270-6","article-title":"Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients","volume":"93","author":"Bargon","year":"1999","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201810-1919OC","article-title":"Changing Prevalence of Lower Airway Infections in Young Children with Cystic Fibrosis","volume":"200","author":"Breuer","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/mmy\/myv119","article-title":"Chronic Aspergillus fumigatus colonization of the pediatric cystic fibrosis airway is common and may be associated with a more rapid decline in lung function","volume":"54","author":"Saunders","year":"2016","journal-title":"Med. Mycol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"00014","DOI":"10.1183\/23120541.00014-2016","article-title":"Respiratory infection rates differ between geographically distant paediatric cystic fibrosis cohorts","volume":"2","author":"Ramsey","year":"2016","journal-title":"ERJ Open Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3109\/00365548.2012.695454","article-title":"Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients","volume":"44","author":"Fillaux","year":"2012","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s10096-015-2474-y","article-title":"Aspergillus fumigatus chronic colonization and lung function decline in cystic fibrosis may have a two-way relationship","volume":"34","author":"Noni","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2019.08.008","article-title":"The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis","volume":"19","author":"Hong","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/cir399","article-title":"Inflammatory Responses to Individual Microorganisms in the Lungs of Children With Cystic Fibrosis","volume":"53","author":"Gangell","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/rccm.201908-1585OC","article-title":"Aspergillus Infections and Progression of Structural Lung Disease in Children with Cystic Fibrosis","volume":"201","author":"Breuer","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/thoraxjnl-2018-211550","article-title":"Aspergillus and progression of lung disease in children with cystic fibrosis","volume":"74","author":"Harun","year":"2019","journal-title":"Thorax"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classifica-tion criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105683","DOI":"10.1016\/j.mimet.2019.105683","article-title":"The prevalence of Aspergillus fumigatus in early cystic fibrosis disease is underestimated by culture-based diagnostic methods","volume":"164","author":"Reece","year":"2019","journal-title":"J. Microbiol. Methods"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/myc.12103","article-title":"Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Asper-gillus quantitative PCR","volume":"57","author":"Fraczek","year":"2014","journal-title":"Mycoses"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Armstead, J., Morris, J., and Denning, D.W. (2014). Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098502"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Briard, B., Mislin, G.L.A., Latg\u00e9, J.-P., and Beauvais, A. (2019). Interactions between Aspergillus fumigatus and Pulmonary Bacteria: Current State of the Field, New Data, and Future Perspective. J. Fungi, 5.","DOI":"10.3390\/jof5020048"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Granchelli, A.M., Adler, F.R., Keogh, R.H., Kartsonaki, C., Cox, D.R., and Liou, T.G. (2018). Microbial Interactions in the Cystic Fibrosis Airway. J. Clin. Microbiol., 56.","DOI":"10.1128\/JCM.00354-18"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","article-title":"Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis","volume":"9","author":"Esther","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00859-17","DOI":"10.1128\/IAI.00859-17","article-title":"Aspergillus fumigatus Preexposure Worsens Pathology and Improves Control of Mycobacterium abscessus Pulmonary Infection in Mice","volume":"86","author":"Monin","year":"2017","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1093\/mmy\/myy087","article-title":"Aspergillus-Pseudomonas interaction, relevant to competition in airways","volume":"57","author":"Sass","year":"2019","journal-title":"Med Mycol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1574-6968.2010.02130.x","article-title":"Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation","volume":"313","author":"Mowat","year":"2010","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1128\/AAC.00234-08","article-title":"Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibil-ity on bronchial epithelial cells","volume":"52","author":"Seidler","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4187\/aarc0492","article-title":"Bugs, biofilms, and resistance in cystic fibrosis","volume":"54","author":"Davies","year":"2009","journal-title":"Respir. Care"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Shirazi, F., Ferreira, J.A.G., Stevens, D.A., Clemons, K.V., and Kontoyiannis, D.P. (2016). Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150155"},{"key":"ref_45","first-page":"e00345-17","article-title":"Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of As-pergillus fumigatus Biofilm","volume":"200","author":"Sass","year":"2017","journal-title":"J. Bacteriol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Melloul, E., Luiggi, S., Ana\u00efs, L., Arn\u00e9, P., Costa, J.-M., Fihman, V., Briard, B., Dannaoui, E., Guillot, J., and Decousser, J.-W. (2016). Characteristics of Aspergillus fumigatus in Association with Stenotrophomonas maltophilia in an In Vitro Model of Mixed Biofilm. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166325"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"574028","DOI":"10.3389\/fcimb.2020.574028","article-title":"Modulated Response of Aspergillus fumigatus and Stenotrophomonas maltophilia to Antimicrobial Agents in Polymicrobial Biofilm","volume":"10","author":"Roisin","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2014.08.007","article-title":"Allergic bronchopulmonary aspergillosis","volume":"2","author":"Greenberger","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1183\/13993003.01475-2015","article-title":"A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"47","author":"Agarwal","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tracy, M.C., Okorie, C.U.A., Foley, E.A., and Moss, R.B. (2016). Allergic Bronchopulmonary Aspergillosis. J. Fungi, 2.","DOI":"10.3390\/jof2020017"},{"key":"ref_51","first-page":"46","article-title":"Allergic bronchopulmonary aspergillosis\u2014A clinical review","volume":"60","author":"Gupta","year":"2012","journal-title":"J. Assoc. Physicians India"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","article-title":"A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergil-losis Complicating Asthma","volume":"153","author":"Agarwal","year":"2018","journal-title":"Chest"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mai.2003.1388","article-title":"Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial","volume":"111","author":"Wark","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1801159","DOI":"10.1183\/13993003.01159-2018","article-title":"A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmo-nary aspergillosis complicating asthma","volume":"52","author":"Agarwal","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/02770903.2014.958853","article-title":"Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)","volume":"52","author":"Chishimba","year":"2014","journal-title":"J. Asthma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00151829-200504040-00004","article-title":"Anti-inflammatory medications for cystic fibrosis lung disease: Selecting the most appropriate agent","volume":"4","author":"Chmiel","year":"2005","journal-title":"Treat. Respir. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1183\/13993003.01816-2015","article-title":"Treating allergic bronchopulmonary aspergillosis: The way forward","volume":"47","author":"Moss","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1164\/rccm.201001-0087OC","article-title":"IgE Sensitization toAspergillus fumigatusIs Associated with Reduced Lung Function in Asthma","volume":"182","author":"Fairs","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_61","first-page":"1117","article-title":"Surface hydrophobin prevents immune recognition of airborne fungal spores","volume":"460","author":"Aimanianda","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1067\/mai.2003.57","article-title":"Allergen detection from 11 fungal species before and after germination","volume":"111","author":"Green","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-7961-4-11","article-title":"Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA","volume":"4","author":"Kurup","year":"2006","journal-title":"Clin. Mol. Allergy"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cea.12333","article-title":"Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: A sys-tematic review","volume":"44","author":"Moreira","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3109\/02770903.2016.1154073","article-title":"Fungal sensitisation in severe asthma is associated with the identification of Aspergillus fumigatus in spu-tum","volume":"53","author":"Farrant","year":"2016","journal-title":"J. Asthma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/EC.00041-08","article-title":"Stress, Drugs, and Evolution: The Role of Cellular Signaling in Fungal Drug Resistance","volume":"7","author":"Cowen","year":"2008","journal-title":"Eukaryot. Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.2012.06816.x","article-title":"Aspergillus bronchitis without significant immunocompromise","volume":"1272","author":"Chrdle","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1378\/chest.100.3.813","article-title":"Adjunctive Therapy of Allergic Bronchopulmonary Aspergillosis with Itraconazole","volume":"100","author":"Denning","year":"1991","journal-title":"Chest"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/cid\/cir179","article-title":"High-frequency Triazole Resistance Found in Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease","volume":"52","author":"Denning","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1093\/jac\/dkaa212","article-title":"Revision of EUCAST breakpoints: Consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators","volume":"75","author":"Guinea","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gonzalez-Jimenez, I., Lucio, J., Amich, J., Cuesta, I., Arroyo, R.S., Alcazar-Fuoli, L., and Mellado, E. (2020). A Cyp51B Mutation Contributes to Azole Resistance in Aspergillus fumigatus. J. Fungi, 6.","DOI":"10.3390\/jof6040315"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1378\/chest.115.2.364","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis: Role of atopy and re-sponse to itraconazole","volume":"115","author":"Nepomuceno","year":"1999","journal-title":"Chest"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/02770903.2012.662568","article-title":"Voriconazole and Posaconazole Improve Asthma Severity in Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitization","volume":"49","author":"Chishimba","year":"2012","journal-title":"J. Asthma"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/mmy\/myz015","article-title":"Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease","volume":"58","author":"Patel","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcf.2005.05.019","article-title":"Voriconazole therapy in children with cystic fibrosis","volume":"4","author":"Hilliard","year":"2005","journal-title":"J. Cyst. Fibros."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/jac\/dkz075","article-title":"Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibro-sis","volume":"74","author":"Periselneris","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3476(95)70343-8","article-title":"A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group","volume":"126","author":"Eigen","year":"1995","journal-title":"J. Pediatr."},{"key":"ref_78","first-page":"103","article-title":"Correlates of osteopenia in patients with cystic fibrosis","volume":"97","author":"Bhudhikanok","year":"1996","journal-title":"Pediatrics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1358\/dot.2013.49.3.1921234","article-title":"Current treatment options for invasive aspergillosis","volume":"49","author":"Batista","year":"2013","journal-title":"Drugs Today"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/02770903.2015.1127935","article-title":"A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis","volume":"53","author":"Ram","year":"2016","journal-title":"J. Asthma"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/myc.12996","article-title":"An evaluation of nebulised amphotericin B deoxycholate (Fungizone\u00a9) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre","volume":"62","author":"Otu","year":"2019","journal-title":"Mycoses"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jaip.2019.01.056","article-title":"Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: Case reports and literature review","volume":"7","author":"Parisi","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/JAA.S156049","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"11","author":"Ashkenazi","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","article-title":"Making sense of itraconazole pharmacokinetics","volume":"56","author":"Prentice","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1128\/AAC.45.6.1937-1938.2001","article-title":"Sputum Itraconazole Concentrations in Cystic Fibrosis Patients","volume":"45","author":"Lenoir","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Aaron, S.D., Vandemheen, K.L., Freitag, A., Pedder, L., Cameron, W., Lavoie, A., Paterson, N., Wilcox, P., Rabin, H., and Tullis, E. (2012). Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036077"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jac\/dkaa382","article-title":"Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital","volume":"76","author":"Abbotsford","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/bcp.13645","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease","volume":"84","author":"Singh","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bcp.14166","article-title":"A phase 1\/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmat-ics to study safety, tolerability and pharmacokinetics","volume":"86","author":"Hava","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_93","first-page":"PA958","article-title":"EDRY\u00ae an Innovative Dry Powder Technology Evaluated via Functional Respiratory Imaging","volume":"48","author":"Caponetti","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejpb.2012.04.019","article-title":"Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice","volume":"81","author":"Beinborn","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2012.03.010","article-title":"Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing","volume":"429","author":"Beinborn","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e02280-16","DOI":"10.1128\/AAC.02280-16","article-title":"In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection","volume":"61","author":"Colley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e00690","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2021","journal-title":"Pharmacol. Res. Perspect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/4\/357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:53:14Z","timestamp":1760363594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/4\/357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,28]]},"references-count":97,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["antibiotics10040357"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10040357","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,28]]}}}